Mosaic Biosciences and Uniquity Bio Announce Strategic Collaboration in Biologics Development

Published: August 4, 2026 | Category: News, Partnerships

---

Mosaic Biosciences today announced a strategic collaboration with Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. The collaboration brings together Mosaic’s platform-agnostic biologics discovery expertise with Uniquity Bio’s scientific rigor and clinical-stage pipeline to advance high-quality biologic candidates with the speed and precision that development programs demand.

---

A Science-First Partnership

Uniquity Bio is a clinical-stage company backed by Blackstone Life Sciences, advancing therapeutic programs in immunology and inflammation with the standards of a global pharma company and the operational agility of a biotech. Its lead asset, solrikitug, is a highly potent monoclonal antibody targeting TSLP across multiple respiratory and gastrointestinal indications with significant unmet need.

The collaboration pairs that clinical-stage ambition with Mosaic’s integrated discovery model, spanning in vitro display, single B-cell methods, transgenic animal platforms, and emerging AI-enabled screening approaches, to support programs where biology, not platform availability, drives every decision.

“We built Mosaic around the belief that the best discovery strategy is one tailored to the biology, not the platform. Uniquity Bio shares that science-first philosophy, and we’re proud to support their mission to bring meaningful new medicines to patients.”

— Jean-Pierre Wery, CEO, Mosaic Biosciences

---

What the Collaboration Delivers

The partnership combines Mosaic’s deep expertise in biologics discovery and lead optimization with Uniquity Bio’s focus on developing medicines for indications with significant unmet need. Together, the two organizations aim to move high-quality biologic candidates forward with the scientific depth and strategic coordination that clinical-stage programs require.

“Mosaic brings a level of scientific depth and strategic partnership in support of clinical-stage and discovery programs that goes beyond traditional CRO relationships. Their integrated approach and broad discovery capabilities align well with how we think about advancing our pipeline.”

— Kiyomi Komori, VP of Translational Medicine, Uniquity Bio

---

Read the full press release here.

---